Related Experiment Videos
Fludarabine phosphate therapy in other lymphoid malignancies
H M Kantarjian1, J R Redman, M J Keating
1Department of Hematology, M. D. Anderson Cancer Center, Houston 77030.
Seminars in Oncology
|October 1, 1990
Summary
Fludara I.V. (fludarabine phosphate) shows promise in treating various B-cell and T-cell cancers. Significant responses were observed in specific lymphomas and leukemias, warranting further investigation.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Fludara I.V. (fludarabine phosphate) has demonstrated efficacy in indolent B-cell neoplasms.
- This success prompted further investigation into its use for other hematologic malignancies.
Purpose of the Study:
- To evaluate the efficacy of Fludara I.V. in a broader range of B-cell and T-cell malignancies.
- To assess response rates in uncommon lymphoid cancers and Hodgkin's disease.
Main Methods:
- Clinical evaluation of Fludara I.V. treatment.
- Assessment of response rates in patients with various hematologic malignancies.
Main Results:
- Significant response rates observed in macroglobulinemic lymphoma.
- Positive outcomes noted in prolymphocytic leukemia and its variants.
- Promising results in mycosis fungoides.
- Interesting preliminary data in hairy-cell leukemia and Hodgkin's disease.
Conclusions:
- Fludara I.V. is a potentially effective treatment for several unusual B-cell and T-cell malignancies.
- Further research is warranted to fully establish its role in hairy-cell leukemia and Hodgkin's disease.